In Vitro Hemocompatibility of Arabinogalactan, Betulin, and Betulin Derivatives
The hemocompatibility of arabinogalactan, betulin and its derivatives was evaluated in vitro and samples suitable for creation of nanostructures or materials in contact with blood were selected. The prospects of arabinogalactan as a component of the construct (nanostructure) for drug delivery are du...
Gespeichert in:
| Veröffentlicht in: | Bulletin of experimental biology and medicine 2024-09, Vol.177 (5), p.621-625 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 625 |
|---|---|
| container_issue | 5 |
| container_start_page | 621 |
| container_title | Bulletin of experimental biology and medicine |
| container_volume | 177 |
| creator | Drozd, N. N. Kuznetsova, S. A. Skurydina, E. S. Vasilieva, N. Yu Levdansky, V. A. |
| description | The hemocompatibility of arabinogalactan, betulin and its derivatives was evaluated
in vitro
and samples suitable for creation of nanostructures or materials in contact with blood were selected. The prospects of arabinogalactan as a component of the construct (nanostructure) for drug delivery are due to the fact that it did not affect blood/plasma coagulation (at concentrations of 0.0033-3.333 mg/ml and 0.00465-4.65 mg/ml, respectively), platelet aggregation (0.00182-0.182 mg/ml), and demonstrated the degree of erythrocyte hemolysis less than 3%. Sodium salt of betulin monosulfate, diarginine salt of betulin disulfate (up to 0.465 mg/ml), and especially betulin and allobetulin formate with procoagulant properties (degree of hemolysis less than 2%) can be used to create a material, for example, sponge, gel, active against blood coagulation. |
| doi_str_mv | 10.1007/s10517-024-06236-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3111206937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3111206937</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-2935274660d1cd7cbe571198dca4e3eee6ab3e3f77b93327e10bce4e881855be3</originalsourceid><addsrcrecordid>eNp9kE1P3DAQhq2qqCy0f6AHFKmXHgh4PIntHPlqQULaC-3VcpxZZJTEi52sxL-vl2VbqQdO9sjP-471MPYV-Blwrs4T8BpUyUVVcilQlviBLaBWWGoh4CNb8EyVldb6kB2l9LQduYRP7BAbrJSWzYIt78bit59iKG5pCC4Mazv51vd-einCqriItvVjeLS9dZMdT4tLmube54sdu_1QXFP0m5zbUPrMDla2T_Tl7Txmv37cPFzdlvfLn3dXF_elE7WcStFgLVQlJe_Adcq1VCuARnfOVoREJG2LhCul2gZRKALeOqpIa9B13RIes--73nUMzzOlyQw-Oep7O1KYk0EAEFw2qDL67T_0KcxxzL_bUggNSC0yJXaUiyGlSCuzjn6w8cUAN1vdZqfbZN3mVbfBHDp5q57bgbq_kb3fDOAOSPlpfKT4b_c7tX8AGXeJtg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3113191682</pqid></control><display><type>article</type><title>In Vitro Hemocompatibility of Arabinogalactan, Betulin, and Betulin Derivatives</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><creator>Drozd, N. N. ; Kuznetsova, S. A. ; Skurydina, E. S. ; Vasilieva, N. Yu ; Levdansky, V. A.</creator><creatorcontrib>Drozd, N. N. ; Kuznetsova, S. A. ; Skurydina, E. S. ; Vasilieva, N. Yu ; Levdansky, V. A.</creatorcontrib><description>The hemocompatibility of arabinogalactan, betulin and its derivatives was evaluated
in vitro
and samples suitable for creation of nanostructures or materials in contact with blood were selected. The prospects of arabinogalactan as a component of the construct (nanostructure) for drug delivery are due to the fact that it did not affect blood/plasma coagulation (at concentrations of 0.0033-3.333 mg/ml and 0.00465-4.65 mg/ml, respectively), platelet aggregation (0.00182-0.182 mg/ml), and demonstrated the degree of erythrocyte hemolysis less than 3%. Sodium salt of betulin monosulfate, diarginine salt of betulin disulfate (up to 0.465 mg/ml), and especially betulin and allobetulin formate with procoagulant properties (degree of hemolysis less than 2%) can be used to create a material, for example, sponge, gel, active against blood coagulation.</description><identifier>ISSN: 0007-4888</identifier><identifier>ISSN: 1573-8221</identifier><identifier>EISSN: 1573-8221</identifier><identifier>DOI: 10.1007/s10517-024-06236-3</identifier><identifier>PMID: 39347869</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Animals ; Anticoagulants ; Antioxidants ; Arabinogalactan ; Betulinic Acid ; Biocompatible Materials - chemistry ; Biocompatible Materials - pharmacology ; Biomedical and Life Sciences ; Biomedicine ; Blood coagulation ; Blood Coagulation - drug effects ; Blood platelets ; Cell Biology ; Cell cycle ; Drug delivery ; Erythrocytes - drug effects ; Galactans - chemistry ; Galactans - pharmacology ; Hematology ; Hemolysis ; Hemolysis - drug effects ; Humans ; Internal Medicine ; Laboratory Medicine ; Materials Testing ; Medical research ; Pathology ; Physiology ; Plasma ; Platelet aggregation ; Platelet Aggregation - drug effects ; Research centers ; Triterpenes - chemistry ; Triterpenes - pharmacology</subject><ispartof>Bulletin of experimental biology and medicine, 2024-09, Vol.177 (5), p.621-625</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-2935274660d1cd7cbe571198dca4e3eee6ab3e3f77b93327e10bce4e881855be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10517-024-06236-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10517-024-06236-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39347869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Drozd, N. N.</creatorcontrib><creatorcontrib>Kuznetsova, S. A.</creatorcontrib><creatorcontrib>Skurydina, E. S.</creatorcontrib><creatorcontrib>Vasilieva, N. Yu</creatorcontrib><creatorcontrib>Levdansky, V. A.</creatorcontrib><title>In Vitro Hemocompatibility of Arabinogalactan, Betulin, and Betulin Derivatives</title><title>Bulletin of experimental biology and medicine</title><addtitle>Bull Exp Biol Med</addtitle><addtitle>Bull Exp Biol Med</addtitle><description>The hemocompatibility of arabinogalactan, betulin and its derivatives was evaluated
in vitro
and samples suitable for creation of nanostructures or materials in contact with blood were selected. The prospects of arabinogalactan as a component of the construct (nanostructure) for drug delivery are due to the fact that it did not affect blood/plasma coagulation (at concentrations of 0.0033-3.333 mg/ml and 0.00465-4.65 mg/ml, respectively), platelet aggregation (0.00182-0.182 mg/ml), and demonstrated the degree of erythrocyte hemolysis less than 3%. Sodium salt of betulin monosulfate, diarginine salt of betulin disulfate (up to 0.465 mg/ml), and especially betulin and allobetulin formate with procoagulant properties (degree of hemolysis less than 2%) can be used to create a material, for example, sponge, gel, active against blood coagulation.</description><subject>Animals</subject><subject>Anticoagulants</subject><subject>Antioxidants</subject><subject>Arabinogalactan</subject><subject>Betulinic Acid</subject><subject>Biocompatible Materials - chemistry</subject><subject>Biocompatible Materials - pharmacology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Blood coagulation</subject><subject>Blood Coagulation - drug effects</subject><subject>Blood platelets</subject><subject>Cell Biology</subject><subject>Cell cycle</subject><subject>Drug delivery</subject><subject>Erythrocytes - drug effects</subject><subject>Galactans - chemistry</subject><subject>Galactans - pharmacology</subject><subject>Hematology</subject><subject>Hemolysis</subject><subject>Hemolysis - drug effects</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Laboratory Medicine</subject><subject>Materials Testing</subject><subject>Medical research</subject><subject>Pathology</subject><subject>Physiology</subject><subject>Plasma</subject><subject>Platelet aggregation</subject><subject>Platelet Aggregation - drug effects</subject><subject>Research centers</subject><subject>Triterpenes - chemistry</subject><subject>Triterpenes - pharmacology</subject><issn>0007-4888</issn><issn>1573-8221</issn><issn>1573-8221</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1P3DAQhq2qqCy0f6AHFKmXHgh4PIntHPlqQULaC-3VcpxZZJTEi52sxL-vl2VbqQdO9sjP-471MPYV-Blwrs4T8BpUyUVVcilQlviBLaBWWGoh4CNb8EyVldb6kB2l9LQduYRP7BAbrJSWzYIt78bit59iKG5pCC4Mazv51vd-einCqriItvVjeLS9dZMdT4tLmube54sdu_1QXFP0m5zbUPrMDla2T_Tl7Txmv37cPFzdlvfLn3dXF_elE7WcStFgLVQlJe_Adcq1VCuARnfOVoREJG2LhCul2gZRKALeOqpIa9B13RIes--73nUMzzOlyQw-Oep7O1KYk0EAEFw2qDL67T_0KcxxzL_bUggNSC0yJXaUiyGlSCuzjn6w8cUAN1vdZqfbZN3mVbfBHDp5q57bgbq_kb3fDOAOSPlpfKT4b_c7tX8AGXeJtg</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Drozd, N. N.</creator><creator>Kuznetsova, S. A.</creator><creator>Skurydina, E. S.</creator><creator>Vasilieva, N. Yu</creator><creator>Levdansky, V. A.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>202409</creationdate><title>In Vitro Hemocompatibility of Arabinogalactan, Betulin, and Betulin Derivatives</title><author>Drozd, N. N. ; Kuznetsova, S. A. ; Skurydina, E. S. ; Vasilieva, N. Yu ; Levdansky, V. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-2935274660d1cd7cbe571198dca4e3eee6ab3e3f77b93327e10bce4e881855be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Anticoagulants</topic><topic>Antioxidants</topic><topic>Arabinogalactan</topic><topic>Betulinic Acid</topic><topic>Biocompatible Materials - chemistry</topic><topic>Biocompatible Materials - pharmacology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Blood coagulation</topic><topic>Blood Coagulation - drug effects</topic><topic>Blood platelets</topic><topic>Cell Biology</topic><topic>Cell cycle</topic><topic>Drug delivery</topic><topic>Erythrocytes - drug effects</topic><topic>Galactans - chemistry</topic><topic>Galactans - pharmacology</topic><topic>Hematology</topic><topic>Hemolysis</topic><topic>Hemolysis - drug effects</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Laboratory Medicine</topic><topic>Materials Testing</topic><topic>Medical research</topic><topic>Pathology</topic><topic>Physiology</topic><topic>Plasma</topic><topic>Platelet aggregation</topic><topic>Platelet Aggregation - drug effects</topic><topic>Research centers</topic><topic>Triterpenes - chemistry</topic><topic>Triterpenes - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Drozd, N. N.</creatorcontrib><creatorcontrib>Kuznetsova, S. A.</creatorcontrib><creatorcontrib>Skurydina, E. S.</creatorcontrib><creatorcontrib>Vasilieva, N. Yu</creatorcontrib><creatorcontrib>Levdansky, V. A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Bulletin of experimental biology and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drozd, N. N.</au><au>Kuznetsova, S. A.</au><au>Skurydina, E. S.</au><au>Vasilieva, N. Yu</au><au>Levdansky, V. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vitro Hemocompatibility of Arabinogalactan, Betulin, and Betulin Derivatives</atitle><jtitle>Bulletin of experimental biology and medicine</jtitle><stitle>Bull Exp Biol Med</stitle><addtitle>Bull Exp Biol Med</addtitle><date>2024-09</date><risdate>2024</risdate><volume>177</volume><issue>5</issue><spage>621</spage><epage>625</epage><pages>621-625</pages><issn>0007-4888</issn><issn>1573-8221</issn><eissn>1573-8221</eissn><abstract>The hemocompatibility of arabinogalactan, betulin and its derivatives was evaluated
in vitro
and samples suitable for creation of nanostructures or materials in contact with blood were selected. The prospects of arabinogalactan as a component of the construct (nanostructure) for drug delivery are due to the fact that it did not affect blood/plasma coagulation (at concentrations of 0.0033-3.333 mg/ml and 0.00465-4.65 mg/ml, respectively), platelet aggregation (0.00182-0.182 mg/ml), and demonstrated the degree of erythrocyte hemolysis less than 3%. Sodium salt of betulin monosulfate, diarginine salt of betulin disulfate (up to 0.465 mg/ml), and especially betulin and allobetulin formate with procoagulant properties (degree of hemolysis less than 2%) can be used to create a material, for example, sponge, gel, active against blood coagulation.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>39347869</pmid><doi>10.1007/s10517-024-06236-3</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-4888 |
| ispartof | Bulletin of experimental biology and medicine, 2024-09, Vol.177 (5), p.621-625 |
| issn | 0007-4888 1573-8221 1573-8221 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3111206937 |
| source | MEDLINE; Springer Online Journals Complete |
| subjects | Animals Anticoagulants Antioxidants Arabinogalactan Betulinic Acid Biocompatible Materials - chemistry Biocompatible Materials - pharmacology Biomedical and Life Sciences Biomedicine Blood coagulation Blood Coagulation - drug effects Blood platelets Cell Biology Cell cycle Drug delivery Erythrocytes - drug effects Galactans - chemistry Galactans - pharmacology Hematology Hemolysis Hemolysis - drug effects Humans Internal Medicine Laboratory Medicine Materials Testing Medical research Pathology Physiology Plasma Platelet aggregation Platelet Aggregation - drug effects Research centers Triterpenes - chemistry Triterpenes - pharmacology |
| title | In Vitro Hemocompatibility of Arabinogalactan, Betulin, and Betulin Derivatives |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T09%3A59%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vitro%20Hemocompatibility%20of%20Arabinogalactan,%20Betulin,%20and%20Betulin%20Derivatives&rft.jtitle=Bulletin%20of%20experimental%20biology%20and%20medicine&rft.au=Drozd,%20N.%20N.&rft.date=2024-09&rft.volume=177&rft.issue=5&rft.spage=621&rft.epage=625&rft.pages=621-625&rft.issn=0007-4888&rft.eissn=1573-8221&rft_id=info:doi/10.1007/s10517-024-06236-3&rft_dat=%3Cproquest_cross%3E3111206937%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3113191682&rft_id=info:pmid/39347869&rfr_iscdi=true |